Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Drug Dev Res ; 76(3): 123-31, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25958838

RESUMO

Bencycloquidium bromide (BCQB), a novel M3 receptor antagonist, alleviates airway hyperresponsiveness, inflammation, and airway remodeling in a murine model of asthma. The aim of this study was to investigate the anti-inflammatory activity of inhaled BCQB in a cigarette smoke (CS)-induced model of acute lung inflammation. Mice exposed to CS developed chronic obstructive pulmonary disease (COPD). Inhalation of BCQB suppressed the accumulation of neutrophils and macrophages in airways and lung and also inhibited the CS-induced increases in mRNA levels of keratinocyte-derived chemokine, monocyte chemotactic protein-1, tumor necrosis factor-alpha, and interleukin-1ß in lung and protein expression levels in bronchoalveolar lavage fluid. Moreover, BCQB (300 µg/ml) inhibited the CS-induced changes in superoxide dismutase and myeloperoxidase activities in the lungs. Our study suggests that BCQB might be a potential therapy for inflammation in CS-induced pulmonary diseases, including COPD.


Assuntos
Compostos Bicíclicos Heterocíclicos com Pontes/administração & dosagem , Modelos Animais de Doenças , Nicotiana/efeitos adversos , Pneumonia/tratamento farmacológico , Receptor Muscarínico M3/antagonistas & inibidores , Fumaça/efeitos adversos , Administração por Inalação , Animais , Relação Dose-Resposta a Droga , Feminino , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Pulmão/patologia , Camundongos , Camundongos Endogâmicos ICR , Pneumonia/metabolismo , Pneumonia/patologia , Fumar/efeitos adversos , Fumar/metabolismo , Fumar/patologia , Resultado do Tratamento
2.
Food Chem Toxicol ; 68: 290-6, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24685824

RESUMO

Chronic fatigue accumulation increases the incidence of cardiovascular disease while the treatment of antioxidants could prevent this development. We have previously shown that quercetin-3-O-gentiobiose (QG), a flavonoid isolated from tonic herb Okra, possesses anti-oxidative properties. In the present study, the protective effects of QG were evaluated in a rat model of load-induced endurance swimming. Oral administration of QG at the doses of 25-75mg/kg could significantly improve the endurance capability of rats to fatigue along with decrease serum lactic acid and blood urea nitrogen levels were decreased. Moreover, QG could alleviate vascular impairments, enhance the activities of antioxidant enzymes and attenuate the levels of inflammatory cytokines (MCP-1, IL-6 and TNF-α). The results indicated that QG had anti-fatigue and vasoprotective effects and represented a potential agent for the treatment of aortic pathology involved with fatigue- and related syndrome.


Assuntos
Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/patologia , Fadiga/tratamento farmacológico , Glicosídeos/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Quercetina/análogos & derivados , Administração Oral , Animais , Antioxidantes/farmacologia , Quimiocina CCL2/sangue , Interleucina-6/sangue , Masculino , Condicionamento Físico Animal , Quercetina/farmacologia , Ratos , Ratos Sprague-Dawley , Fator de Necrose Tumoral alfa/sangue , Doenças Vasculares/tratamento farmacológico , Doenças Vasculares/etiologia , Doenças Vasculares/patologia
3.
Carbohydr Polym ; 102: 543-9, 2014 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-24507317

RESUMO

Lilii Bulbus is a popular folk medicine in the worldwide and has attracted great attention due to its bioactivity against respiratory system diseases (include lung cancers). This study was the first report providing in vivo evidences of antitumor potential of the bioactive polysaccharide from Lilii Bulbus. One major fraction (LBP-1) was obtained by purifying the crude polysaccharides extracted from Lilii Bulbus. Chemical characterization analysis indicated that LBP-1 was only a glucan, whose average molecular weight was 30.5 kDa. Intraperitoneal administration of LBP-1 at the doses of 50-200mg/kg significantly inhibited the growth of Lewis lung carcinoma. Moreover, it could also obviously increase macrophage phagocytosis, splenocytes proliferation and cytokine (TNF-α, IL-2, IL-6 and IL-12) production to participate in the antitumor effects. LBP-1 could act as antitumor agent with immunomodulatory activity.


Assuntos
Adjuvantes Imunológicos/farmacologia , Antineoplásicos/farmacologia , Medicamentos de Ervas Chinesas/química , Polissacarídeos/farmacologia , Animais , Carcinoma Pulmonar de Lewis/patologia , Ensaios de Seleção de Medicamentos Antitumorais , Cromatografia Gasosa-Espectrometria de Massas , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Polissacarídeos/química , Polissacarídeos/isolamento & purificação , Solubilidade , Espectrofotometria Infravermelho , Água/química
4.
J Zhejiang Univ Sci B ; 6(2): 125-31, 2005 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15633248

RESUMO

Epigallocatechin-3-gallate (EGCG) has shown remarkably anti-cancer activity, with its bioactivity being related to reactive conditions, such as pH and metal ions. The present study investigated the degradation of EGCG and its effect on prostate cancer cell in the presence of Cu2+. EGCG was incubated with prostate cancer cells, LNCaP, pretreated with or without Cu2+. EGCG in F-12 medium was quantified using HPLC and the viability of cells was assessed by gel electrophoresis, flow cytometry, and electron microscope. The results of HPLC showed that EGCG degraded completely within 12 h in F-12 medium with or without Cu2+. Gel electrophoresis and flow cytometry did not detect apoptosis of LNCaP cells when they were incubated with EGCG. Electron microscopy examination revealed that EGCG-Cu2+ complex led to damage of cytoplasm membrane in LNCaP cells. It was speculated that not EGCG, but its oxide and complex with Cu2+, are the bioactive components responsible for its cytotoxicity to LNCaP prostate cancer cells.


Assuntos
Catequina/análogos & derivados , Catequina/administração & dosagem , Cobre/administração & dosagem , Cobre/metabolismo , Neoplasias da Próstata/patologia , Neoplasias da Próstata/fisiopatologia , Anticarcinógenos/administração & dosagem , Apoptose/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Combinação de Medicamentos , Humanos , Masculino , Neoplasias da Próstata/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA